67 – Cytokine Biology

[1]  M. Labow,et al.  Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  L. Moldawer,et al.  TNF-α Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung1 , 2000, The Journal of Immunology.

[3]  L. Moldawer,et al.  Discordant tumor necrosis factor-alpha superfamily gene expression in bacterial peritonitis and endotoxemic shock. , 1999, Surgery.

[4]  T. Standiford,et al.  IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. , 1999, Journal of immunology.

[5]  J. Crawford,et al.  Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. , 1998, Seminars in oncology.

[6]  R. Colman,et al.  Recombinant Tumor Necrosis Factor Receptor p75 Fusion Protein (TNFR:Fc) Alters Endotoxin-Induced Activation of the Kinin, Fibrinolytic, and Coagulation Systems in Normal Humans , 1998, Thrombosis and Haemostasis.

[7]  K. Oshimi,et al.  Differential Effects of Anti-Fas Ligand and Anti-Tumor Necrosis Factor α Antibodies on Acute Graft-Versus-Host Disease Pathologies , 1998 .

[8]  L. Moldawer,et al.  Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. , 1998, Journal of applied physiology.

[9]  R. Huber,et al.  Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Maier,et al.  Evidence that brief stress may induce the acute phase response in rats. , 1997, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  C. Dinarello,et al.  Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. , 1997, Chest.

[12]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[13]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[14]  L. Moldawer,et al.  Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. , 1997, Journal of vascular surgery.

[15]  G. Kollias,et al.  Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice , 1997, European journal of immunology.

[16]  H. Bruining,et al.  p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial , 1997 .

[17]  M. Kamm,et al.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease , 1997, The Lancet.

[18]  S. Chandler,et al.  Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview , 1997, Journal of Neuroimmunology.

[19]  S. Banks,et al.  Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. , 1996, Blood.

[20]  S. Paul,et al.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. van der Poll,et al.  Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. , 1996, Blood.

[22]  J. Vauthey,et al.  A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon , 1996, The Journal of experimental medicine.

[23]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[24]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[25]  M. Cuesta,et al.  Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. , 1996, Blood.

[26]  R. Locksley,et al.  The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.

[27]  J. Dipiro,et al.  Interleukin-10 is associated with the development of sepsis in trauma patients. , 1996, The Journal of trauma.

[28]  S. Calvano,et al.  Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. , 1996, Journal of immunology.

[29]  G. Fantuzzi,et al.  Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. , 1996, Blood.

[30]  M. Kotb,et al.  Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. , 1996, American journal of surgery.

[31]  B. Scallon,et al.  Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. , 1995, Cytokine.

[32]  D. Remick.  Cytokines: A Primer for Plastic Surgeons , 1995, Annals of plastic surgery.

[33]  T. L. Nagabhushan,et al.  Crystal structure of interleukin 10 reveals an interferon gamma-like fold. , 1995, Biochemistry.

[34]  A Wlodawer,et al.  Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. , 1995, Structure.

[35]  L. Shapiro,et al.  A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. , 1995, Journal of immunology.

[36]  J. Spivak,et al.  Clinical use of erythropoietin , 1995, Current opinion in hematology.

[37]  S. Calvano,et al.  Influence of IL-1 receptor blockade on the human response to endotoxemia. , 1995, Journal of immunology.

[38]  D. Carvajal,et al.  Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist , 1995, European journal of immunology.

[39]  S. Marsters,et al.  Molecular and biological properties of an interleukin-1 receptor immunoadhesin. , 1994, Molecular immunology.

[40]  I. Chaudry,et al.  Mechanism of enhanced susceptibility to sepsis following hemorrhage. Interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release. , 1994, Archives of surgery.

[41]  T. van der Poll,et al.  Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees , 1994, The Journal of experimental medicine.

[42]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[43]  J. Born,et al.  Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. , 1994, The Journal of clinical endocrinology and metabolism.

[44]  B. Dörken,et al.  Lymphotoxin‐α/β heterodimer is expressed on leukemic hairy cells and activated human B lymphocytes , 1994 .

[45]  Ho As,et al.  Interleukin-10 and its receptor. , 1994 .

[46]  S. Calvano,et al.  A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon , 1994, The Journal of experimental medicine.

[47]  R. de Waal Malefyt,et al.  Expression cloning and characterization of a human IL-10 receptor. , 1994, Journal of immunology.

[48]  S. Marsters,et al.  Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. , 1994, Blood.

[49]  G. Chrousos,et al.  Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. , 1993, The Journal of clinical endocrinology and metabolism.

[50]  J. Mier,et al.  Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. , 1993, Blood.

[51]  C. Dinarello,et al.  Measuring circulating cytokines. , 1993, Journal of applied physiology.

[52]  L. Moldawer,et al.  Cachexia and the acute‐phase protein response in inflammation are regulated by interleukin‐6 , 1993, European journal of immunology.

[53]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[54]  D. Longo,et al.  The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin , 1993 .

[55]  J. Mier,et al.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. , 1992, Cytokine.

[56]  B. Millar,et al.  Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations. , 1992, Journal of immunological methods.

[57]  W. Fiers,et al.  Selective species specificity of tumor necrosis factor for toxicity in the mouse. , 1992, Lymphokine and cytokine research.

[58]  S. Joel,et al.  Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. , 1992, Journal of immunological methods.

[59]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[60]  S. Suter,et al.  High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. , 1992, The American review of respiratory disease.

[61]  D. Remick,et al.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.

[62]  D. Goeddel,et al.  Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Dripps,et al.  Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. , 1991, The Journal of biological chemistry.

[64]  H. Büller,et al.  Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans , 1991 .

[65]  D. Longo,et al.  Phase I Evaluation of Recombinant Tumor Necrosis Factor Given in Combination With Recombinant Interferon-Gamma , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[66]  R. Cooper,et al.  Relationships between local inflammation, interleukin‐6 concentration and the acute phase protein response in arthritis patients , 1991, European journal of clinical investigation.

[67]  H. Tabuchi,et al.  Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. , 1991, The Journal of biological chemistry.

[68]  T. J. Hayes,et al.  Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. , 1991, The American journal of physiology.

[69]  W. Buurman,et al.  Evaluation of measurement of human TNF in plasma by ELISA. , 1991, Lymphokine and cytokine research.

[70]  T. Mosmann,et al.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[71]  T. Fahey,et al.  Interleukin 1 receptor blockade attenuates the host inflammatory response. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[72]  A C Allison,et al.  The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. , 1990, The Journal of clinical investigation.

[73]  J. Gauldie,et al.  IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-6. , 1990, Journal of immunology.

[74]  A M Gronenborn,et al.  Determination of the secondary structure of interleukin-8 by nuclear magnetic resonance spectroscopy. , 1989, The Journal of biological chemistry.

[75]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[76]  R. Schreiber,et al.  Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. , 1989, Journal of immunology.

[77]  J. Philippé,et al.  Influence of blood-collecting systems on concentrations of tumor necrosis factor in serum and plasma. , 1988, Clinical chemistry.

[78]  A. Waage,et al.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.

[79]  T. Prangé,et al.  Structure of tumour necrosis factor by X-ray solution scattering and preliminary studies by single crystal X-ray diffraction. , 1988, Journal of molecular biology.

[80]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[81]  L. Moldawer,et al.  Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. , 1987, The American journal of physiology.

[82]  J. D. Albert,et al.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. , 1987, Surgery, gynecology & obstetrics.

[83]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[84]  A. C. Webb,et al.  Expression of biologically active human interleukin 1 subpeptides by transfected simian COS cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Dinarello.  Interleukin-1 and the pathogenesis of the acute-phase response. , 1984, The New England journal of medicine.

[86]  A. Goldberg,et al.  Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. , 1983, The New England journal of medicine.

[87]  G. H. Clowes,et al.  Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. , 1983, The New England journal of medicine.

[88]  T. Robak,et al.  Research Paper Mediators of Inflammation, 7, 347–353 (1998) , 2022 .

[89]  Lawrence Sp,et al.  Advances in the treatment of hepatitis C. , 2000 .

[90]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[91]  M. Gately,et al.  Characterization of anti-mouse IL-12 monoclonal antibodies and measurement of mouse IL-12 by ELISA. , 1996, Journal of immunological methods.

[92]  C. Dinarello,et al.  Cytokines as mediators in the pathogenesis of septic shock. , 1996, Current topics in microbiology and immunology.

[93]  K. Tracey,et al.  Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.

[94]  P. Barie,et al.  Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. , 1990, Surgery, gynecology & obstetrics.

[95]  L. Moldawer,et al.  Identification of a novel tumor necrosis factor alpha/cachectin from the livers of burned and infected rats. , 1990, Archives of surgery.

[96]  J. Meer,et al.  Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. , 1988, Lymphokine research.

[97]  K. Tracey,et al.  Physiological responses to cachectin. , 1987, Ciba Foundation symposium.

[98]  A. C. Webb,et al.  Human and murine interleukin 1 possess sequence and structural similarities. , 1985, The Journal of molecular and cellular immunology : JMCI.